Clinical trial · Interventional
Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer
Eight Week Plant-based Mediterranean Diet as Prevention of Metabolic Syndrome in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A BrUOG Pilot Study
NCT01083771CI-TRIAL-00056900completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess for changes in a patient's overall energy level and well-being (quality of life) after 8 weeks of dietary intervention.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Olive Oil | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Olive Oil
- description
- At least 3 tablespoons of olive oil each day
- interventionNames
- Dietary Supplement: Olive Oil
Primary outcomes (1)
- measure
- Changes in the Blood Chemistry (Fasting Triglycerides) After 8 Weeks of Following a Mediterranean Diet
- timeFrame
- eight weeks
- description
- Based on overall percentage change at baseline versus post diet
Secondary outcomes (1)
- measure
- To Assess Changes in the Body After 8 Weeks of Following a Mediterranean Diet
- timeFrame
- 8 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically documented carcinoma of the prostate * On treatment with androgen deprivation therapy for at least 3 months * Required laboratory values: * Serum creatinine less than 2.5 * Triglycerides \<300 * Fasting glucose \< 126 * Testosterone level \<50 Exclusion Criteria: * No diabetes mellitus (Type 1 or 2) * No renal failure (Serum creatinine \> 2.5) * No active cardiac disease -no history of myocardial infarction/stroke within the last 12 months, no recurrent unstable angina, uncontrolled/unstable arrhythmias, uncontrolled hypertension (systolic blood pressure \>160, diastolic blood pressure \>100) * No severe peripheral vascular disease * No commencement of lipid lowering agent within 8 weeks of enrollment the study or change in dose throughout the study
References
Publications (0)
Data not yet available
No reference posted for this study.